Diagnosis and management of hyperlipidaemia

International Journal of Clinical Practice

Volumn 51, Issue 6, 1997, Pages 378-383

  Wierzbicki, A S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; CHOLESTEROL; CLOFIBRATE; COLESTYRAMINE; GEMFIBROZIL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; ATHEROMA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MALE; META ANALYSIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK FACTOR; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; RISK FACTORS;

EID: 0030794791     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Kannel WB, Castelli WP, Gordon T, McNamara P. Serum cholesterol lipoproteins and risk of coronary heart disease: the Framingham Study. Ann Intern Med 1971; 74: 1-12.
2. Neaton JD, Wentworth JP for the Multiple Risk Factor Intervention Group. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Arch Intern Med 1992; 152: 56-64.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study.(4S). Lancet 1994; 344: 1383-1389.
4. Sachs FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996; 335: 1001-1009.
5. McMurray JJV. Primary and secondary prevention of coronary heart disease by cholesterol reduction. Recent clinical trial data. Br J Cardiol 1996; 3(Suppl 1): S12-S19.
6. Byington RP, Jukema JW, Salonen T et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events in the atherosclerosis intervention program. Circulation 1995; 92: 2419-2425.
7. Johanneson M, Jonsson B, Kjekshus J et al. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. New Engl J Med 1997; 336: 322-326.
8. The Post-Coronary Artery Bypass Graft Trial investigators. The effect of aggressive cholesterol lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary bypass grafts. New Engl J Med 1997; 336: 153-162.
9. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. New Engl J Med 1987; 317: 1237-1245.
10. Lipid Research Clinics Program. The Lipid Research Clinics Primary prevention trial. Results I: Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
11. Lipid Research Clinics Program. The Lipid Research Clinics Primary prevention trial. Results II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 364-375.
12. Buchwald H, Campos CT, Boen JR et al. Disease free interval after partial ileal bypass in patients with coronary artery disease and hypercholesterolemia: results from the Program on Surgical Control of Hyperlipidemia (POSCH). J Am Coll Cardiol 1995; 26: 351-357.
13. Vaughn CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-1082.
14. Linden T, Bondjers G, Karlsson T, Wiklund O. Serum triglycerides and HDL cholesterol: major predictors of long-term survival after coronary surgery. Eur Heart J 1994; 15: 747-752.
15. Ericcson C-G, Hamsten A, Nilsson J et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post-infarction patients (BECAIT). Lancet 1996; 347: 849-853.
16. Assman G, Schulte H. Role of triglycerides in coronary artery disease: lessons from the prospective cardiovascular Munster Study. Am J Cardiol 1992; 70: 10H-13H.
17. Tenkanen L, Manttari M, Mattinen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 1995; 92: 1779-1785.
18. Austin MA, Edwards KL. Small dense low density lipoproteins, insulin resistance syndrome and non-insulin dependent diabetes mellitus. Curr Opin Lipidol 1996; 7: 167-171.
19. Grundy SM. Small LDL, atherogenic dyslipidemia and the metabolic syndrome. Circulation 1997; 95: 1-4.
20. Miller BD, Alderman EL, Haskell WL et al. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996; 94: 2146-2153.
21. Lamarche B, Tcherhof A, Moorjani S et al. Small dense low-density lipoprotein particles as a predictor of risk of ischemic heart disease in men. Circulation 1997; 95: 69-75.
22. Hennekens CH. Anti-oxidant vitamins and cardiovascular disease: current perspectives and future directions. Eur Heart J 1997; 18: 177-179.
23. Stephens NG, Parsons A, Schofield P et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Anti-oxidant study (CHAOS). Lancet 1996; 347: 781-786.
24. Duell PB, Malinow MR. Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol 1997; 8: 28-35.
25. Anonymous. Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 patients in 45 prospective cohorts. Prospective Trials Collaboration. Lancet 1995; 346: 647-653.
26. Levensen J, Giral P, Rozavian M et al. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arteriosclerosis 1995; 15: 1263-1238.
27. O'Brien KD, Reichenbach DD, Marcovina SM et al. Apolipoproteins B (a) and E accumulate in morphologically early lesions of 'degenerative' valvular aortic stenosis. Arteriosclerosis 1996; 16: 523-532.
28. Andrews TC, Raby K, Barry J et al. Effect of cholesterol reduction on myocardial ischaemia in patients with coronary disease. Circulation 1997; 95: 324-328.
29. WHO Committee of Principal Investigators. Report on a cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-1118.
30. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339-1343.
31. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345: 1274-1275.
32. Grodstein F, Stampfer MJ, Manson M-J et al. Post-menopausal oestrogen and progestin and risks of cardiovascular disease. New Engl J Med 1996; 335: 453-461.
33. Bush TL. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J 1996; 17(Suppl D): 9-14.
34. Pyorala K, De Backer G, Poole-Wilson P, Wood D on behalf of the task force. Prevention of coronary heart disease in clinical practice: recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-1331.
35. Betteridge DJ, Dodson PM, Durrington PN et al. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993; 69: 359-369.
36. Ramsay LE, Haq IU, Jackson PR et al. Targeting lipid lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996; 348: 387-388.
37. Gotto AM. Heart disease and the assessment and treatment of hypercholesterolaemia, coronary artery disease and other atherosclerotic diseases, family history and left ventricular hypertrophy. Am J Med 1994; 96(Suppl): 9S-18S.
38. Durrington PN, Ishola M, Hunt L et al. Apolipoprotein (a), A-1, and B and parental history in men with early onset ischaemic heart disease. Lancet 1988; i: 1070-1073.
39. Williams SRP, Jones E, Bell W et al. Body habitus and coronary heart disease in men. Eur Heart J 1997; 18: 376-393.
40. Bhatnagar D, Anand IS, Durrington P et al. Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet 1995; 345: 405-409.
41. Uterman G. The mysteries of lipoprotein (a). Science 1989; 246: 905-910.
42. Wade DP. Lipoprotein (a). Curr Opin Lipidol 1993; 4: 244-249.
43. Orth-Gomer K, Mittleman MA, Schenk-Gustafsson K et al. Lipoprotein (a) as a determinant of coronary heart disease in young women. Circulation 1997; 95: 329-334.
44. Terres W, Tatsis E, Pfalzer B et al. Rapid progression of coronary artery disease in patients with elevated lipoprotein (a). Circulation 1995; 91: 948-950.
45. Meade TW, Ruddock V, Stirling Y et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
46. Fowkes FG. Fibrinogen and cardiovascular disease in clinical practice. Eur Heart J 1995; 16(Suppl A): 60-63.
47. Anonymous. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989; 12: 573-579.
48. Pyorala K, Pedersen TR, Kjekshus J et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-620.
49. Laasko M. Epidemiology of diabetic dyslipidaemia. Diabetes Rev 1995; 3: 463-524.
50. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of efficacy and safety. Eur Heart J 1995; 16: 5-13.
51. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance haemodialysis. New Engl J Med 1974; 290: 697-701.
52. Toto RJ, Vega GL, Grundy SM. Mechanisms and treatment of dyslipidaemias of renal disease. Curr Opin Nephrol Hypertens 1993; 2: 784-790.
53. Packard CJ, Shepherd J. Current concepts in the treatment of familial hypercholesterolaemia Curr Opin Lipidol 1995; 6: 57-61.
54. Anonymous. Identification and management of heterozygous familial hypercholesterolaemia. Proceedings of a workshop. July 20-21, 1992. Am J Cardiol 1993; 72: 1D-84D.
55. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparison with familial hypercholesterolaemia. Atherosclerosis 1993; 104: 1-18.
56. Ferriere J, Lambert J, Lussier-Cacon S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolaemia with the same LDL receptor mutation. Circulation 1995; 92: 290-295.
57. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolaemia. Hum Mutation 1992; 1: 445-466.
58. Naoumova RP, Marias D, Firth JC et al. Atorvastatin augments therapy of homozygous familial hypercholesterolaemia by inhibiting upregulation of cholesterol synthesis after apheresis and bile acid sequestrants. American Heart Association 96 abstracts. Arteriosclerosis 1996; 16(Suppl 1); 41. Abstarct 09239.
59. Jarvik GP, Brunzell JD, Austin MA et al. Genetic predictors of FCHL in four large pedigrees: influence of apoB level major locus predicted genotype and LDL subclass phenotype. Arteriosclerosis 1994; 14: 1687-1694.
60. ASPIRE steering group. A British Cardiac Society survey of potential for secondary prevention of coronary disease: ASPIRE (action on secondary prevention through interaction to reduce events). Heart 1996; 75: 334-342.